Licogliflozin

N/A

Report date: 2024/11/14 20:00:08
NME

Base Information

Drug NameLicogliflozin
Drug Alias Namelicogliflozin diprolinatelicogliflozin bis(prolinate)LIK-066
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium/glucose cotransporter 1 inhibitorsSodium/glucose cotransporter 2 inhibitors
TargetsSodium/glucose cotransporter 2Sodium/glucose cotransporter 1
Therapy Area/IndicationsOverweightObesityDiabetes Mellitus, Type 2 +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[36] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesChina Novartis Institutes For Biomedical Research Co Ltd
Inactive CompaniesNovartis Pharma Ag
Active IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsOverweightObesityDiabetes Mellitus, Type 2 +[7] 

Other Information

ATC CodeN/A
Related LinksN/A